For the quarter ending 2025-09-30, VCYT had $96,057K increase in cash & cash equivalents over the period. $41,965K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Total revenue | 376,509 | - |
| Laboratory supplies and reagents expense | 43,134 | - |
| Sample collection expense | 9,398 | - |
| Compensation expense | 17,906 | - |
| Other cost | 14,017 | - |
| Allocation of facilities and it expenses | 9,989 | - |
| Cost of revenue-Testing | 94,444 | - |
| Product costs | 1,864 | - |
| License fees and royalties | 888 | - |
| Other cost | 2,980 | - |
| Allocation of facilities and it expenses | 454 | - |
| Cost of revenue-Product | 6,186 | - |
| Compensation expense | 3,318 | - |
| Other cost | 3,118 | - |
| Allocation of facilities and it expenses | 925 | - |
| Cost of revenue-Biopharmaceutical And Other | 7,361 | - |
| Intangible asset amortization - cost of revenue | 7,959 | - |
| Gross profit | 260,559 | - |
| Compensation expense | 27,840 | - |
| Direct expense | 10,946 | - |
| Other research and development expenses | 5,278 | - |
| Allocation of facilities and it expenses | 5,901 | - |
| Total research and development | 49,965 | - |
| Compensation expense | 52,214 | - |
| Direct expense | 3,564 | - |
| Other selling and marketing expenses | 10,880 | - |
| Allocation of facilities and it expenses | 7,567 | - |
| Total selling and marketing | 74,225 | - |
| Compensation expense | 62,121 | - |
| Other general and administrative expenses | 56,132 | - |
| Allocation of facilities and it expenses | -24,836 | - |
| Total general and administrative | 93,417 | - |
| Impairment of assets | 20,505 | - |
| Intangible asset amortization - operating expenses-Intangible Asset Amortization | 1,865 | - |
| Other income, net | 6,985 | - |
| Income tax (benefit) provision | 2,363 | - |
| Net income | 19,137 | 6,067 |
| Depreciation and amortization | 5,266 | 10,851 |
| Loss on disposal of property, plant and equipment | 0 | -15 |
| Stock-based compensation | 10,757 | 21,943 |
| Deferred income taxes | -87 | 74 |
| Noncash lease expense | 689 | 1,600 |
| Revaluation of acquisition-related contingent consideration | 166 | -2,879 |
| Effect of foreign currency on operations | -1,205 | 5,050 |
| Amortization of discount on short-term investments | 2,619 | - |
| Impairment loss | 0 | 20,505 |
| Non-cash loss on deconsolidation of subsidiary | -3,863 | - |
| Accounts receivable | -425 | 4,283 |
| Supplies and inventory | -221 | 2,863 |
| Prepaid expenses and other current assets | 956 | 5,460 |
| Other assets | -1,720 | 1,389 |
| Operating lease liabilities | -495 | -1,186 |
| Accounts payable | -3,660 | 3,113 |
| Accrued liabilities and deferred revenue | 9,125 | -2,091 |
| Net cash provided by operating activities | 44,757 | 38,967 |
| Acquisition of c2i, net of cash acquired | 0 | 0 |
| Purchase of short-term investments | 0 | 99,998 |
| Proceeds from maturity of short-term investments | 51,055 | 51,061 |
| Purchases of property, plant and equipment | 2,792 | 3,105 |
| Net cash used in investing activities | 48,263 | -52,042 |
| Payment of taxes on vested restricted stock units | 2,814 | 11,831 |
| Proceeds from the exercise of common stock options and employee stock purchases | 5,791 | 4,781 |
| Net cash (used in) provided by financing activities | 2,977 | -7,050 |
| Increase in cash, cash equivalents and restricted cash | 95,997 | -20,125 |
| Effect of foreign currency on cash, cash equivalents and restricted cash | 60 | 647 |
| Net increase in cash, cash equivalents and restricted cash | 96,057 | -19,478 |
| Cash and cash equivalents at beginning of period | 240,631 | - |
| Cash and cash equivalents at end of period | 317,210 | - |
VERACYTE, INC. (VCYT)
VERACYTE, INC. (VCYT)